Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-blind, Vehicle-controlled Efficacy and Safety Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis

Trial Profile

A Phase 3, Randomized, Double-blind, Vehicle-controlled Efficacy and Safety Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glycopyrrolate (Primary)
  • Indications Hyperhidrosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ATMOS-2
  • Sponsors Journey Medical Corporation
  • Most Recent Events

    • 01 Mar 2019 According to a Dermira media release, results of post hoc analysis from ATMOS-1 and ATMOS-2 studies were presented at the Annual Meeting of the American Academy of Dermatology (AAD) 2019.
    • 01 Mar 2019 Results of post hoc analysis from ATMOS-1 and ATMOS-2 studies presented in a Dermira media release.
    • 26 Feb 2019 According to a Dermira media release, data from post hoc analyses of the ATMOS-1 and ATMOS-2 will be presented at the 77th Annual Meeting of the American Academy of Dermatology (AAD).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top